In the context of amphetamine-induced behavioral sensitization in mice, DNQX demonstrates the capacity to block both the onset and the manifestation of this sensitization. Rather than impacting the overall amphetamine activity, DNQX specifically intervenes in the sensitization process. This phenomenon might be attributed to the activation of excitatory amino acid receptors which subsequently provoke an increased dopamine release in the striatum. Therefore, DNQX's actions appear to be both potent and specific hinting at complex mechanisms beyond traditional ionotropic glutamate receptor pathways.[3]
An activation of both AMPA/kainate and dopaminergic receptors in the nucleus accumbens may be crucial for the reward response triggered by psychostimulant drugs. Dopaminergicantagonists often do not prevent the acquisition of a conditioned place preference for cocaine, a common measure of drug reward. In experiments where DNQX, an AMPA receptorantagonist, was injected into the nucleus accumbens prior to systemic cocaine administration, it diminished the acquisition of this place preference, highlighting AMPA receptors' role in this process. Conversely, the dopaminergicantagonistfluphenazine did not alter cocaine-induced place preference, possibly due to adaptations following repeated drug exposure. Both DNQX and fluphenazine blocked the expression of conditioned place preference in rats previously trained with cocaine alone, indicating the involvement of both AMPA and dopaminergicreceptors in the expression of cocaine-induced place preference.[4]